UCB off to a good start into 2024

Belgium’s largest drugmaker UCB (Euronext: UCB) today announced an update on its progress at its annual shareholder meeting (AGM), with the news edging its shares up 1.7% to 122.90 by midday.

“We are excited to share the progress on our growth path for a decade plus,” said Jean-Christophe Tellier, chief executive of UCB. “We had a good start into the year 2024, tracking well towards our full year financial guidance. Our ongoing launches are getting positive feedback from patients and healthcare professionals. The positive prescription trends for Bimzelx are continuing nicely in all regions where approved and available for patients. Additionally, the first months of 2024 have been marked for Bimzelx by five fillings by the US FDA, an approval in the EU, and of course the approval of Rystiggo in the EU,” he added.

UCB noted that Bimzelx (bimekizumab-bkzx) has seen continued strong uptake in the USA, where it was approved in October 2023 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug is now approved in 42 countries.